Mobile

A multi center study to assess the safety and efficacy of nab-paclitaxel with CC-486, nab-paclitaxel with MEDI4736 and nab-paclitaxel alone as 2nd/3rd line treatment in subjects with advanced NSCLC

Update Il y a 4 ans
Reference: EUCTR2014-001105-41

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To estimate the efficacy of nab-paclitaxel administered intravenously (IV) on Days 8 and 15 with epigenetic modifying therapy of CC-486 once daily (QD) on Days 1 to 14 every 21 days or nab-paclitaxel administered intravenously (IV) on Days 1 and 8 with immunotherapy of durvalumab administered IV on Day 15 every 21 days, and nab-paclitaxel monotherapy administered IV on Days 1 and 8 every 21 days as second/third-line treatment for advanced NSCLC.

Inclusion criteria

  • Advanced non-small cell lung cancer (NSCLC)

Links